Abstract

Hepatitis B Core-Related Antigen Point-of-Care Tests as a Risk Stratification Tool for Treatment Eligibility: Experience From Kenya

Downs LO, Okanda D, Chirro O, Zaharani M, Safari B, Aliyan N, Andersson MI, Tanaka Y, Etyang AO, Shimakawa Y, Githinji G, Matthews PC
Open Forum Infect Dis. 2025;12

Permenent descriptor
https://doi.org/10.1093/ofid/ofaf125


We undertook a point-of-care test for hepatitis B core-related antigen in adults with hepatitis B virus in Kilifi, Kenya. A positive test identified all individuals with a hepatitis B viral load >200 000 IU/mL and who were hepatitis B e antigen positive. It also correlated with a higher alanine aminotransferase (ALT) level (P = .03), raised aspartate transaminase-to-platelet ratio index (APRI) (P < .001), and higher elastography scores (P = .03).

Publication metrics
Dimensions Badge

Altmetric

Key Terms
Hbv | hepatitis B core-related antigen | liver disease | point-of-care diagnostics | treatment | for lectures from Gilead Sciences and research materials from Abbott Laboratories | and Fujirebio Inc. P.C.M. has previously received funding support for her group | from GSK (outside the scope of this paper). Y.T. has received scholarship | donations from AbbVie GK and OTSUKA Pharmaceutical Co. and research funding from | AbbVie GK, Fujirebio Inc, Sysmex Corp, GSK, Gilead Sciences, and Janssen (Source: Medline)
Funded by
Francis Crick Institute (Ref: CC2223) | Wellcome Trust (grant number 225485/Z/22/Z) | Oxford University Hospitals NHS Foundation Trust Oxford Hospitals Charity Grant ref 1351 | Japan Society for the Promotion of Science KAKENHI grant (JP21K10416)
External Sources
Abstract at pubmed
Full text at publishers website
Full text at PMC